Senseonics (NYSE:SENS) today priced an upcoming offering, looking to raise approximately $25 million to support its Eversense long-term implantable continuous glucose monitoring system. The Germantown, Md.-based company said it will look to float 11.6 million shares in the offering at a price of $2.15 per share. The offering will also include a 30-day underwriter’s option to […]
Senseonics
Senseonics expects FDA panel to consider Eversense CGM clearance
Senseonics (NYSE:SENS) said it expects the FDA will convene a special panel as it considers the company’s implantable Eversense continuous glucose monitors. The clarity came during the company’s 2nd quarter earnings call last week, with CEO Tim Goodnow saying the company expected the federal watchdog to look to an advisory panel, similar to its actions with Dexcom‘s (NSDQ:DXCM) […]
Senseonics inks artificial pancreas deal with Roche, TypeZero Technologies
Senseonics (NYSE:SENS) said today that it inked a collaboration with TypeZero Technologies and Roche (OTC:RHHBY) Diabetes Care to develop an automated insulin delivery system. The deal is part of an NIH-funded effort to test artificial pancreas systems. The trial is slated to integrate Senseonic’s Eversense glucose monitor, TypeZero’s inControl AP algorithms and Roche’s Accu-Chek Insight insulin pump. The software automatically […]
Senseonics, TypeZero ink development deal for artificial pancreas
Senseonics (NYSE:SENS) said yesterday that it inked a non-exclusive R&D license agreement with TypeZero Technologies to develop artificial pancreas and decision support systems for its Eversense continuous glucose monitor. The companies plan to integrate glucose readings from the Eversense system with TypeZero’s inControl artificial pancreas algorithms to regulate insulin delivery through a user’s insulin pump. […]
Lombard Medical CEO Hubbert, CFO Kullback step down | Personnel Moves, April 28, 2017
Lombard Medical Technologies (NSDQ:EVAR) said this month that its CEO Simon Hubbert and CFO William Kullback are stepping down from their positions, with Kurt Lemvigh stepping into the CEO role. Hubbert served as CEO for 6 years after joining the company in 2010, and will be replaced by Lemvigh, who has held positions with multiple companies, including […]
Senseonics draws 3rd $5m tranche for implantable CGM
Senseonics (NYSE:SENS) said last month that it drew the 3rd installment of $5 million under its term loan facility with Oxford Finance and Silicon Valley Bank. The 3rd tranche, which closed on March 29 this year, was triggered by the 1st sale of the Germantown, Maryland-based company’s 2nd-gen transmitter in Europe. Senseonics previously borrowed $20 million […]
RTI Surgical names new CEO, parts ways with CSO Hartill | Personnel Moves | January 31, 2017
RTI Surgical (NSDQ:RTIX) named Camille Farhat as its chief executive officer, effective March 15, 2017. Previously, Farhat served as president & CEO of American Medical Systems, Inc., where he helped facilitate Boston Scientific (NYSE:BSX)’s $1.65 billion acquisition of the men’s and prostate health businesses. He has also held leadership positions with Baxter (NYSE:BAX), Medtronic (NYSE:MDT) and General Electric (NYSE:GE). “Today […]
Dexcom surges on Medicare nod for continuous glucose monitors
DexCom (NSDQ:DXCM) said yesterday that the Centers for Medicare & Medicaid classified therapeutic continuous glucose monitors as durable medical equipment under Medicare Part B. The company’s Dexcom G5 Mobile is the only CGM system that falls under this classification, according to San Diego, Calif.-based DexCom, since patients can make treatment decisions using the device. DXCM […]
Senseonics prelim beat Q4 estimates
Senseonics (NYSE:SENS) saw shares rise 5.6% today after it released preliminary financial results for the 4th quarter, beating analysts’ expectations on Wall Street. The Germantown, Md.-based company said it expects a total revenue of $0.3 million for Q4 and for the year ended December 31, 2016, ahead of consensus on The Street, where analysts were looking for […]
Senseonics, Roche expand distribution deal for Eversense glucose monitor
Senseonics (NYSE:SENS) said today that it expanded its exclusive distribution agreement with Roche (PINK:RHHBY) for its implantable continuous glucose monitoring system for people with diabetes. The new agreement includes all of Europe, the Middle East and Africa, excluding Scandinavia, Finland and Israel. According to the agreement, Germantown, Maryland-based Senseonics has given Roche exclusive rights to promote, […]
Senseonics submits FDA PMA application for Eversense CGM
Senseonics (NYSE:SENS) said today it submitted a premarket approval application to the FDA for its Eversense continuous glucose monitoring system. The Eversense system includes an implanted glucose sensor designed to last up to 90 days, as well as a wearable smart transmitter designed to calculate glucose levels. The devices work in tandem with a mobile application that […]